Echinatin

Echinatin

SCHEMBL618086

COc1cc(O)ccc1/C=C/C(=O)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CTSL P07711 5/20 1.00
CTSB P07858 5/20 1.00
TDP1 Q9NUW8 1/20 1.00
CAPN1 P07384 2/20 0.78
CYP1A1 P04798 1/20 0.78
CYP1B1 Q16678 1/20 0.78
MAOB P27338 1/20 0.74
DPP4 P27487 3/20 0.71
TNFRSF1A P19438 1/20 0.69
PTPN1 P18031 1/20 0.69
APP P05067 1/20 0.68
ABCG2 Q9UNQ0 1/20 0.68
CHRNA7 P36544 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Echinatin SCHEMBL29466900 1.00 CTSL (1.00) CTSLCTSBTDP1CAPN1CYP1A1
Echinatin SCHEMBL7193984 1.00 CTSL (1.00) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL26113846 0.93 CTSB (0.86) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL20340332 0.91 CTSL (0.84) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL20340331 0.91 CTSL (0.84) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL7180313 0.90 TNFRSF1A (0.86) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL7180309 0.90 TNFRSF1A (0.86) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL29600833 0.90 TNFRSF1A (0.86) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL8964952 0.85 MAOB (1.00) CTSLCTSBTDP1CAPN1CYP1A1
SCHEMBL29403206 0.85 MAOB (1.00) CTSLCTSBTDP1CAPN1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
CN-118813576-B Protein coded by safflower CtHA gene and application thereof 新疆农业科学院经济作物研究所(新疆维吾尔自治区棉花研究所新疆维吾尔自治区甜菜改良中心) 2025-04-04 CN claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
US-20240360485-A1 PROCESS FOR PREPARATION OF PHLOROGLUCINOL AND PHENOLIC DERIVATIVES EHRHARDT JEFFREY (US) 2024-10-31 US claimed
CN-118813576-A Protein coded by safflower CtHA gene and application thereof 新疆农业科学院经济作物研究所(新疆维吾尔自治区棉花研究所新疆维吾尔自治区甜菜改良中心) 2024-10-22 CN claimed
US-20240285660-A1 COMPOSITION FOR WOUND RELIEF AND INHIBITING A PHD PROTEIN AND METHODS OF TREATMENT CURAPEP LLC (US) 2024-08-29 US claimed
CN-118356431-A Pharmaceutical composition for preventing or treating inflammatory bowel disease, preparation and application thereof 沈阳药科大学 2024-07-19 CN claimed
US-20230012268-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2023-01-12 US claimed
WO-2022232243-A1 COMPOSITIONS FOR WOUND RELIEF AND INHIBITING A PHD PROTEIN AND METHODS OF TREATMENT CURAPEP LLC (US) 2022-11-03 WO claimed
WO-2012021837-A2 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER SENOMYX, INC. (US) 2012-02-16 WO claimed
CN-101596227-A A kind of Chinese herbal and crude drugs preparations for the treatment of advanced lung cancer YIN LIAO (CN) 2009-12-09 CN claimed
CN-101069563-A Beverage composition and method for preventing degradation of vitamins in beverages PEPSICO INC (US) 2007-11-14 CN claimed
US-20070110851-A1 Beverage composition and method of preventing degradation of vitamins in beverages PEPSICO, INC. 2007-05-17 US claimed
EP-1782701-A1 Beverage composition and method of preventing degradation of vitamins in beverages PepsiCo, Inc. (US) 2007-05-09 EP claimed
CN-1599602-A Peroxisome proliferator activated receptor ligands and process for producing the same KANEGAFUCHI CHEMICAL IND (JP) 2005-03-23 CN claimed
US-20050014819-A1 Peroxisome proliferator activated receptor ligands and process for producing the same KANEKA CORPORATION (JP) 2005-01-20 US claimed
EP-1440688-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGANDS AND PROCESS FOR PRODUCING THE SAME KANEKA CORPORATION (JP) 2004-07-28 EP claimed
US-20040091589-A1 Prevention of synthetic color fading in beverages using botanically derived color stabilizers PEPSICO, INC. 2004-05-13 US claimed
EP-0998939-A1 Chalcone plant extracts for use in therapy THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) 2000-05-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014819-A1 Peroxisome proliferator activated receptor ligands and process for producing the same PPARG, PPARA, PPARD CTSL 3528/4885CTSB 4149/4885TDP1 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.